Maintenance therapy adds a long-term expense similar to a subscription model
J Diabetes Complications 2022;36:108255.ArticlePubMed 92
November 1, 2024: FDA Issues Letter Warning People About Compounded GLP-1 Drugs As more pharmacies compound GLP-1 drugs for weight loss, the FDA issued a warning to patients who take these versions of GLP-1 drugs
The consequences of loss of muscle function are far reaching and include decrease of motor control and overall fitness, development of functional limitations and impairment, and long term disability
However, whilst there is no official prohibition against combining these medications, healthcare professionals must carefully consider the indirect metabolic effects that may arise from their concurrent use
15,16 In a laboratory study, canagliflozin reduced T cell activation markers, such as IL-2, in CD4+ T cells from patients with systemic lupus erythematosus (SLE) and RA